Adc Therapeutics SA Forecast, price target & analysts
Adc Therapeutics SA Target price 2026 - Analyst rating & recommendation
Adc Therapeutics SA Classifications & Recommendation
Adc Therapeutics SA Price Target
| Target Price | $2.55 |
| Price | $1.06 |
| Potential |
140.57%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Adc Therapeutics SA 2027 .
The average Adc Therapeutics SA target price is $2.55.
This is
140.57%
register free of charge
$5.25
395.28%
register free of charge
$0.51
52.36%
register free of charge
|
|
| A rating was issued by 12 analysts: 8 Analysts recommend Adc Therapeutics SA to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adc Therapeutics SA stock has an average upside potential 2027 of
140.57%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2031
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 81.36 | 81.94 |
| 14.85% | 0.71% | |
| EBITDA Margin | -132.34% | -141.54% |
| 27.51% | 6.95% | |
| Net Margin | -175.29% | -134.85% |
| 21.33% | 23.07% |
8 Analysts have issued a sales forecast Adc Therapeutics SA 2026 . The average Adc Therapeutics SA sales estimate is
This results in the following potential growth metrics:
7 Adc Therapeutics SA Analysts have issued a net profit forecast 2026. The average Adc Therapeutics SA net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.12 | -0.87 |
| 30.86% | 22.32% | |
| P/E | negative | |
| EV/Sales | 4.04 |
7 Analysts have issued a Adc Therapeutics SA forecast for earnings per share. The average Adc Therapeutics SA EPS is
This results in the following potential growth metrics and future valuations:
Adc Therapeutics SA...
Current Adc Therapeutics SA Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 08 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jun 04 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 05 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 05 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 23 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 17 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 08 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jun 04 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 23 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 16 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
